The pharmaceutical compounding company ImprimisRx LLC has once again run afoul of the US Food and Drug Administration for misleading promotions about one of its products.
The agency’s Division of Pharmaceutical Quality Operations IV sent the company a warning letter in June objecting to claims made about its compounded eye drop product Pred-Moxi-Brom (prednisolone acetate...